Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans Academic Article uri icon


MeSH Major

  • Adjuvants, Immunologic
  • Antibodies, Neoplasm
  • Antigens, Neoplasm
  • CD4-Positive T-Lymphocytes
  • CD8-Positive T-Lymphocytes
  • Cancer Vaccines
  • Membrane Proteins
  • Recombinant Proteins
  • Saponins


  • NY-ESO-1 is a "cancer-testis" antigen expressed in many cancers. ISCOMATRIX is a saponin-based adjuvant that induces antibody and T cell responses. We performed a placebo-controlled clinical trial evaluating the safety and immunogenicity of recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant. Forty-six evaluable patients with resected NY-ESO-1-positive tumors received three doses of vaccine intramuscularly at monthly intervals. The vaccine was well tolerated. We observed high-titer antibody responses, strong delayed-type hypersensitivity reactions, and circulating CD8(+) and CD4(+) T cells specific for a broad range of NY-ESO-1 epitopes, including known and previously unknown epitopes. In an unplanned analysis, vaccinated patients appeared to have superior clinical outcomes to those treated with placebo or protein alone. The vaccine is safe and highly potent immunologically.

publication date

  • July 20, 2004



  • Academic Article



  • eng

PubMed Central ID

  • PMC489997

Digital Object Identifier (DOI)

  • 10.1073/pnas.0403572101

PubMed ID

  • 15252201

Additional Document Info

start page

  • 10697

end page

  • 702


  • 101


  • 29